Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...

IgG4-related sclerosing disease is an immune-mediated disease that affects multiple organs at the same time in some people. This can often include an inflamed pancreas, organ swelling, disease in ...

IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for ...

Related Disease - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of historical and ...

IgG4-related disease is an immune mediated condition that probably has an autoimmune basis, although we don't know that for sure. The disease was first recognized to be a unique condition in 2003 ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of ...

About Immunoglobulin G4-related disease (IgG4-RD) UPLIZNA is a humanized monoclonal antibody (mAb) that causes targeted and sustained depletion of key cells that contribute to underlying disease ...

Beamon set out on a journey, and 26 doctors, 37 procedures and more than 17 years later, a rheumatologist finally cracked the confounding code: She had immune disorder IgG4-related disease ...

Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, ...

Inebilizumab-cdon is the first FDA-approved treatment for IgG4-related disease, targeting CD19+ B cells to reduce inflammation and fibrosis. The MITIGATE trial showed inebilizumab significantly ...

The drug has become the first to receive FDA approval specifically for treating immunoglobulin G4-related disease (IgG4-RD). LAS VEGAS, April 14, 2025 /PRNewswire/ -- IgG4-related disease (IgG4-RD ...

About Immunoglobulin G4-related disease (IgG4-RD) The prevalence is estimated at 20,000 people in the United States (5 in 100,000 worldwide), although the number of IgG4-RD patients is difficult ...